In December 2021 the India National Anti-Doping Agency (INADA) has reported an anti-doping rule violation against the wrestler Shubham after his sample tested positive for the prohibited substance Furosemide.
After notification a provisional suspension was ordered. The Athlete filed a statement in his defence and he was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).
The Athlete accepted the test result and denied the intentional use of the substance. He explained with medical information that in August 2021 he suffered from an urinary infection and its symptoms. He underwent treatment in a hospital and used prescibed Lasix in the days before sample collection.
The Athlete asserted that he was unaware that the prescribed medication contained a prohibited substance. He acknowledged that he did'nt told his doctor that he was an Athlete and he didn't mention his medication on the Doping Control Form. Hereafter he applied for a retroactive TUE which was denied in September 2021 and after an appeal again denied by INADA in November 2021.
The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation. The Panel concludes that the violation was not intentional and that the Athlete acted in this case with some degree of negligence.
Therefore the ADDPI decides on 2 May 2022 to impose a 5 month period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e on 14 December 2021.